[Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2020 Edition)].
Zhonghua Zhong Liu Za Zhi
; 43(1): 78-91, 2021 Jan 23.
Article
en Zh
| MEDLINE
| ID: mdl-33472318
Antibody-drug conjugate (ADC) is a type of targeted biological agent which connect cytotoxic drug to monoclonal antibody by a connector head, which enables monoclonal antibody acted as a carrier to efficiently transport small molecular cytotoxic drugs to target tumor cells. It is very important for clinicians to have an in-depth understanding of the molecular characteristics and mechanism of ADC drugs, rationally choose the appropriate dose, course of treatment and manage adverse reactions according to the indications during the clinical application of ADC drugs, which may even affect the survival of patients. Therefore, the consensus aims to conduct a systematic overview of commercially available ADC drugs, provide effective recommendations and references for clinicians to better apply and manage ADC drugs.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Inmunoconjugados
/
Neoplasias
/
Antineoplásicos
Tipo de estudio:
Guideline
/
Systematic_reviews
Límite:
Humans
Idioma:
Zh
Revista:
Zhonghua Zhong Liu Za Zhi
Año:
2021
Tipo del documento:
Article
Pais de publicación:
China